A new weekly amylin drug shows about 10% weight loss in Phase 2 Petrelintide, a once-weekly amylin-based injection (a different hormone pathway from GLP-1), was tested in 485 adults for 42 weeks. Average weight loss was up to 10.2% when everyone assigned to the drug is counted (up to 10.7% in people while taking it),
